Wedbush downgraded Iveric bio to Neutral from Outperform with a price target of $40, up from $35, after the company entered into a definitive agreement under which Astellas Pharma will acquire 100% of its outstanding shares for $40 per share in cash for a total equity value of $5.9B.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE: